Wells Fargo & Company Issues Pessimistic Forecast for MannKind (NASDAQ:MNKD) Stock Price

MannKind (NASDAQ:MNKD) had its target price decreased by Wells Fargo & Company from $8.00 to $7.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 113.41% from the stock’s current price.

MNKD has been the subject of a number of other reports. Wall Street Zen upgraded shares of MannKind from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Zacks Research lowered MannKind from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 10th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $3.50 price objective (down from $7.50) on shares of MannKind in a report on Friday. Truist Financial set a $9.00 target price on MannKind in a research note on Monday, November 24th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of MannKind in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.21.

MannKind Stock Performance

NASDAQ:MNKD opened at $3.28 on Friday. MannKind has a fifty-two week low of $2.93 and a fifty-two week high of $6.51. The firm has a market cap of $1.01 billion, a PE ratio of 164.08 and a beta of 0.84. The business has a 50 day moving average price of $5.55 and a 200-day moving average price of $5.36.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). The firm had revenue of $111.96 million for the quarter, compared to the consensus estimate of $99.85 million. MannKind had a net margin of 1.68% and a negative return on equity of 11.12%. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.03 earnings per share. Research analysts predict that MannKind will post 0.1 EPS for the current year.

Insider Transactions at MannKind

In related news, CEO Michael Castagna sold 107,920 shares of MannKind stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $5.57, for a total transaction of $601,114.40. Following the completion of the transaction, the chief executive officer directly owned 2,504,792 shares of the company’s stock, valued at $13,951,691.44. This trade represents a 4.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the completion of the sale, the insider owned 985,007 shares in the company, valued at approximately $6,235,094.31. This trade represents a 4.55% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 262,846 shares of company stock valued at $1,546,840. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of MannKind

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV purchased a new position in MannKind during the fourth quarter valued at $70,000. Voloridge Investment Management LLC increased its holdings in shares of MannKind by 50.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,861,046 shares of the biopharmaceutical company’s stock valued at $10,552,000 after acquiring an additional 626,878 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of MannKind in the 4th quarter worth about $182,000. Polymer Capital Management US LLC bought a new position in MannKind in the 4th quarter worth about $168,000. Finally, Man Group plc grew its position in MannKind by 80.9% during the 4th quarter. Man Group plc now owns 178,494 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 79,843 shares during the last quarter. Hedge funds and other institutional investors own 49.55% of the company’s stock.

Trending Headlines about MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.